AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03378466 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Venous thromboprophylaxis (VTE)
Description: May include subcutaneous heparin or dalteparin, sequential compression device or graduated compression stockings
Study NCT01132976 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Personal Concerns Inventory
Description: This is a pre-treatment, goal-based motivational interview which helps to patients identify their life goals, and goal-value. The interview will last approximately 2 hours and will be carried out face to face with a therapist across one or two sessions.
Study NCT01132976 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Treatment as usual
Description: No specific motivational interview
Study NCT02151032 — intervention group
Intervention type: BEHAVIORAL
Intervention: Booklet
Description: Participants read a booklet about colorectal cancer screening tests.
Study NCT02151032 — intervention group
Intervention type: BEHAVIORAL
Intervention: Audio CD
Description: Participants listen to an audio CD that will narrate the colorectal cancer screening tests booklet.
Study NCT02151032 — intervention group
Intervention type: BEHAVIORAL
Intervention: Video with Non-Moving Images
Description: Participants watch a video with non-moving images about colorectal cancer screening tests on an iPad.
Study NCT02151032 — intervention group
Intervention type: BEHAVIORAL
Intervention: Video with Animated Images
Description: Participants watch a video with animated images about colorectal cancer screening tests on an iPad.
Study NCT02151032 — intervention group
Intervention type: BEHAVIORAL
Intervention: Questionnaires
Description: Questionnaire completion before and after viewing the program.
Study NCT01924858 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2647544 oral
Description: GSK2647544 100 mg will be supplied as a size 0 swedish orange hard gelatin capsules filled with white/slightly colored granule. Subjects will receive a single oral dose of GSK2647544 100 mg (2 X 50mg capsules) with 150 mL of tepid water approximately 2 hours prior to the IV infusion of \[18F\]-GSK2647544 and a PET scan.
Study NCT01924858 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [18F]GSK2647544 IV bolus
Description: \[18F\]GSK2647544 will be supplied as a clear, colourless solution free from visible particle. A maximum dose up to 2 mg with a maximum dose volume of 25 mL will be administered as IV bolus over 60 seconds.
Study NCT04168463 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Two Joy for All robots (one cat and one dog)
Description: Intervention will include the opportunity to interact with the Joy for All robot animals.
Study NCT04168463 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Two Joy for All robots (one cat and one dog)
Description: Intervention will include the opportunity to interact with the Joy for All robot animals.
Study NCT01282047 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: oral course, 25 mg, day 1 to 21, per month, 7 days of wash-out each month. Duration according to initial response: 24 weeks and 12 weeks more if complete remission, 24 weeks more if partial remission or stable disease and stop in case of progression.
Study NCT03196947 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APO010
Description: APO010 is given iv on D1, D8 and D15 followed by a one-week drug rest (cycle duration 4 weeks).
Study NCT03003338 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OBV/PTV/r and DSV
Description: OBV/PTV/r (12.5 mg/ 75 mg/ 50 mg) in combination with DSV (250 mg): Two tablets of OBV/PTV/r in the morning and one tablet of DSV in the morning and one tablet of DSV in the evening orally with a meal without regard to fat or calorie content.
Study NCT03003338 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to match OBV/PTV/r and DSV
Description: Placebo to match OBV/PTV/r and DSV
Study NCT01323764 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ShuntCheck test
Description: Non-invasive, thermal dilution test for CSF shunt flow compared to radionuclide shunt patency testing
Study NCT02596334 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dolutegravir 50mg +abacavir 600mg +lamivudine 300mg
Study NCT02596334 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dolutegravir
Study NCT02327195 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylphenidate HCl
Description: Subjects will be randomly assigned to either the Methylphenidate or the Placebo arm, and be given a 20 mg dose (of Methylphenidate or Placebo) in liquid form (4 mL)
Study NCT02327195 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 20 mg of placebo (PO) will be given 2 hours prior to surgery
Study NCT01880034 — intervention group
Intervention type: OTHER
Intervention: Lipid Emulsion Survey
Study NCT00665730 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sepraspray
Study NCT04558554 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacy-based PrEP delivery
Description: The intervention is a new model of PrEP delivery that has never been tried before in an African setting: pharmacy-based PrEP delivery.
Study NCT00493272 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fibrinogen
Description: Fibrinogen behandling
Study NCT00493272 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Fibrinogen
Description: Fibrinogen behandling
Study NCT03487055 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TK006
Description: Subcutaneous injection in the upper arm
Study NCT03106870 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin Mixtard
Description: Insulin dose:~* 0.7 IU/Kg (at the second trimester of pregnancy).~* 0.8 IU/Kg (at the third trimester of pregnancy). Insulin dose was raised at a rate of 1 IU for every 10 mg/dl higher than the target blood glucose concentration.
Study NCT03106870 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: Oral metformin at a dose of 1500 mg divided into three doses, were taken with meals, in addition to insulin.~If the target blood glucose concentrations were not attained, the dose of metformin was raised to 2000 mg per day.
Study NCT00725439 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Talarozole
Description: Oral Dose 1.0 mg once daily
Study NCT00639990 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: PEEP
Description: Application of positive end expiratory pressure
Study NCT00639990 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PEEP
Description: Application of positive end-expiratory pressure
Study NCT01774474 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bromfenac
Study NCT01774474 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Study NCT01774474 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab
Study NCT01774474 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triamcinolone Acetonide
Study NCT02583204 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Onicolife nail drops
Description: The prescription free, CE (Conformité Européenne) marked product is for local application, and has a novel mode of action involving the modulation of mast cell action with the fatty acid amide, Adelmidrol ®. Mast cells are known to have a key role in the ability of the body to promote healing /repair and control tissue damage caused by chemo and radiotherapy. This includes damage to the nail and/ or nail matrix. OnicoLife ® thus helps to control inflammation and pain whilst antimicrobial action also provides antibacterial and antifungal support.
Study NCT02583204 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nail polish
Description: One dark colour of nail polish (deep burgundy/red) will be used in this study since this colour is considered more acceptable to many more women than a pure black coloured nail polish and hence, more likely to ensure compliance. No nail polish containing hardeners will be used since there is some evidence to suggest they can induce nail changes. As dark nail polish can stain the nail plate (and therefore mask any changes in nail pigmentation induced by chemotherapy), one clear base coat, two coats of coloured, and one clear top coat of polish will be required for each application. This standard of application is proposed as a gold standard for the prevention of nail staining and hypersensitivity reactions by an eminent podiatrist (Spalding, 2008).
Study NCT00971893 — intervention group
Intervention type: DRUG
Intervention: Oral Methylprednisolone Tablets
Description: Oral Methylprednisolone tablets given as per locally approved prescribing information
Study NCT01939197 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-450/r/ABT-267
Description: tablet
Study NCT01939197 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-333
Description: tablet
Study NCT01939197 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ribavirin
Description: tablet
Study NCT01432795 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Gliding aids for medical compression stockings
Description: Each subject tests devices:~* 3 gliding aids for stockings with closed tips~* 3 gliding aids for stockings with open tips~* 2 stocking butlers using~* 3 medical compression stockings with open tip, compression class 3 (36-46mmHg)~* 3 medical compression stockings w. closed tip, compression class 3 (36-46mmHg)~* 2 superimposed compression stockings class 1 (18 - 21 mmHg)
Study NCT00048568 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abatacept
Description: Intravenous (IV) Solution, - Weight Titered (500 mg \< 60 kg); (750 mg 60-100 kg), )1 gram > 100 kg), Day 1, Day 15, Day 29; every 28 days thereafter, 1 year
Study NCT00048568 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Tablets, Oral, >= 15 mg, weekly, 1 year
Study NCT00048568 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methotrexate
Description: Tablets, Oral, >= 15 mg, weekly, 1 year
Study NCT00048568 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: IV solution, Intravenous, D5W, Day 1, Day 15, Day 29; every 28 days thereafter, 1 year
Study NCT02252562 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sage Personal Hand Hygiene System
Description: Utilization of a health care provider worn personal hand hygiene system during routine practice in the intra-operative setting with provider specific individual feedback.
Study NCT03541564 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986165
Description: Specified dose on specified days
Study NCT03541564 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Moxifloxacin
Description: Specified dose on specified days
Study NCT03541564 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Specified dose on specified days
Study NCT04033952 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Strategy Training
Description: This approach is different from traditional direct skill training, which emphasizes clinicians' responsibility on identifying their patients' challenges in performing activities and teaching patients task-specific problem-solving strategies. Strategy training, on the other hand, requires clinicians to take a role as a facilitator, guiding participants to learn through prompts and questions. In the training process, participants learn to develop their own problem-solving strategies and work through the problems they have, through which they can develop self-efficacy and confidence to manage participation challenges. Participants can also generalize the strategies they learn to other similar problems they encounter in daily life.
Study NCT02304588 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Mesenchymal stem cells
Description: 10-20 x 10\^6 cells/20mL
Study NCT04955262 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bempegaldesleukin (NKTR-214)
Description: Specified dose on specified days
Study NCT04955262 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Specified dose on specified days
Study NCT04955262 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ⁸⁹Zr-Df-IAB22M2C
Description: Specified dose on specified days
Study NCT01513083 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: trastuzumab emtansine
Description: Multiple intravenous doses
Study NCT01806922 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Yoga
Study NCT01247259 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pangramin®
Description: During a 4-week increasing-dose phase, the patients increased the daily dose from 1 to 5 drops of 1.6 STU/mL solution from day 1 to 10, 1 to 5 drops of 8 STU/mL solution from day 11 to 15, 1 to 5 drops of 40 STU/mL solution from day 16 to 20, 1 to 5 drops of 200 STU/mL solution from day 21 to 25, and 1 to 5 drops of 1000 STU/mL solution from day 26 to 30. After reaching the maintenance dose, 5 drops of 1000 STU/mL solution, the patients took the allergen three times per week during the maintenance phase.
Study NCT02475915 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vorinostat
Description: Vorinostat (suberoylanilide hydroxamic acid) inhibits histone deacetylases class I and II. Vorinostat is supplied as 100mg capsules and will be administered at 400mg/ day in 2 week cycles beginning at week 0 for 10 weeks - 42 doses.
Study NCT02475915 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine
Description: Hydroxychloroquine is supplied as 200mg tablets and will be administered at week 0 for 10 weeks
Study NCT02475915 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Maraviroc
Description: Maraviroc will be administered at 150 to 600mg/ml twice daily depending on the subject's ART regimen at week 0 for 10 weeks
Study NCT02475915 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir
Description: NRTI. Tenofovir will be administered at 300mg 1 X day at week 0 for 10 weeks
Study NCT02475915 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tenofovir
Description: NRTI. Tenofovir will be administered at 300mg 1 X day at week 0 for 10 weeks
Study NCT02475915 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Emtricitabine
Description: NRTI. Emtricitabine will be administered at 200mg 1 X day at week 0 for 10 weeks
Study NCT02475915 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Emtricitabine
Description: NRTI. Emtricitabine will be administered at 200mg 1 X day at week 0 for 10 weeks
Study NCT02475915 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efavirenz
Description: NNRTI. Efavirenz will be administered at 600 mg 1 X day at week 0 for 10 weeks
Study NCT02475915 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Efavirenz
Description: NNRTI. Efavirenz will be administered at 600 mg 1 X day at week 0 for 10 weeks
Study NCT02475915 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darunavir
Description: Protease Inhibitor. Darunavir will be administered at a dose of 900mg 1 X day for subjects on NNRTI based ART beginning at week 8 until week 10
Study NCT02475915 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Darunavir
Description: Protease Inhibitor. Darunavir will be administered at a dose of 900mg 1 X day for subjects on NNRTI based ART beginning at week 8 until week 10
Study NCT04712422 — intervention group
Intervention type: OTHER
Intervention: Healthy subjects
Description: Participants will be tested for their foot dominance by means of the Waterloo footedness questionnaire-revised, their hand dominance by means of the Edinburgh inventory, and their eyedness Coren's Lateral Preference Inventory.~Participants will perform a cervical repositioning test. They will seat in a chair in front of a Plexiglas screen with the eye closed. The operator will guide the participant in four positions: at 30° right/left rotation and at 25° extension/flexion. The participant will be then asked to reproduce the angle. Each movement will be repeated four times in a random order. The whole sequence will be repeated by another second operator. Both the tests will be repeated after two weeks.~Head movements will be detected using an optoelectronic system using passive markers positioned on the head of the participant.
Study NCT04712422 — intervention group
Intervention type: OTHER
Intervention: Pathologic group
Description: Clinical evaluation of the participants will be performed by means of the Myotonic Dystrophy Health Index (MDHI), the Rivermead Mobility Index (RMI), the Fall Events Questionnaire, and the Dizziness Handicap Inventory- short form (DHIsf).~Participants will perform a cervical repositioning test. Participants will seat in a chair in front of a Plexiglas screen with the eye closed. The operator will guide the participant in four positions: at 30° right/left rotation and at 25° extension/flexion. The participant will be then asked to reproduce the angle. Each movement will be repeated four times in a random order.~Head movements will be detected using an optoelectronic system using passive markers positioned on the head of the participant.~Participants will then perform test of balance in standing, using the EquiTest platform. Individuals will be requested to perform three different tasks: sensory organization test, adaptation test-upward tilt, and adaptation test-downward tilt.
Study NCT03602326 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neurodevelopmental Therapy-Bobath group
Description: Neurodevelopmental Therapy-Bobath (NDT-B) is one of the most commonly used models for therapeutic management and treatment in patients with stroke. The basic philosophy underlying this approach is that; lesions in the central nervous system cause impairments in the coordination of movement and posture combined with problems in muscle tone which lead directly to functional limitations. According to the NDT-B approach, practice has a great role in treatment due to the fact that more practice leads to better motor learning and increases neural plasticity. According to NDT-B, the duration of treatment should not be limited to rehabilitation sessions, but should be designed to be implied throughout the day and should be adapted to the patients' daily life.
Study NCT03602326 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standart Rehabilitation Group (SR group)
Description: Standard Rehabilitation for Stroke consists of the hospitals' physiotherapy and rehabilitation routine.
Study NCT02220868 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Sofosbuvir, Ribavirin, and Stribild
Study NCT00526968 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EVT 101
Description: 8 mg capsule, single oral dose
Study NCT00526968 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EVT 101
Description: 15 mg capsule, single oral dose
Study NCT00526968 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Placebo capsule, single oral dose
Study NCT03072680 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: BPS PAST
Description: Participants think about themselves in a past when they displayed their best self. Then, they visualize this with the help of audio instructions.~They will practice within a mobile app.
Study NCT03072680 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: BPS FUT
Description: Participants think about themselves in the future after everything has gone as well as it possibly could. Then, they visualize this with the help of audio instructions.~They will practice within a mobile app.
Study NCT03072680 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: DAILY ACTIVITIES
Description: Participants think about the activities they did during the last 24 hours. Then, they visualize this with the help of audio instructions.~They will practice within a mobile app.
Study NCT05754047 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: immunohistochemistry (IHC) and in situ hybridization (ISH) Test
Description: These tests are usually applied for breast cancer patients to assist the surgeon to better understand the clinicopathological characteristics and survival features of tumors
Study NCT00569062 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GW856553X
Description: GW856553X 7.5mg BID for 6 weeks
Study NCT00569062 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo to match GW856553X
Study NCT00688064 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adapalene BPO Gel associated with Doxycyline Hyclate
Description: Adapalene BPO Gel: Topical to the face, once daily in the evening Doxycycline Hyclate: Oral, 1 tablet once daily in the morning. Both during 12 weeks.
Study NCT00688064 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vehicle Gel associated with Doxycycline Hyclate
Description: Vehicle Gel: Topical to the face, once daily in the evening; Doxycycline Hyclate: Oral, 1 tablet once daily in the morning. Both during 12 weeks.
Study NCT04374084 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Moxibustion plus Cupping
Description: Moxibustion: The burning of a small, thimble sized, smoldering plug of dried leaves on the skin at an acupuncture point. Usually the plugs contain leaves of mugwort or moxa. Cupping takes the pot as a tool, uses the combustion to remove the air in the pot, causes a negative pressure, and makes it adsorb on the skin of the acupoints. UseBaixiaojiumoxibustion on each acupoint for 10-15 minutes, the temperature of moxibustion should be adjusted within patient's tolerance level. Use diameter of 5-6 cm acuum cupper to cupping on each acupoint for 5-8 minutes.